Hepatocellular Carcinoma Detection Using Biomarker Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting hepatocellular carcinoma (HCC) lack sensitivity and specificity, particularly for early detection and in cases where alpha-fetoprotein (AFP) levels are normal.
Innovation Solution
The method involves removing IgG and IgM proteins from a biological fluid, measuring specific biomarkers such as fucosylated glycoproteins, determining the subject's age and gender, and using an optimized function to determine the presence or absence of HCC.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If alpha-fetoprotein (AFP) is used as a primary screen for HCC, then the detection process is simple and widely available, but the sensitivity and specificity are insufficient, particularly for early-stage and AFP-negative HCC
Solution Approach 1:
The detection system is segmented into multiple independent components: IgG and IgM removal modules, multiple biomarker measurement modules (including AFP, AFP-L3, and other serum biomarkers), and an integrated analysis system that combines results from all modules to generate a comprehensive HCC detection outcome
Solution Approach 2:
The patent merges multiple detection approaches into a single integrated system. It combines traditional AFP testing with additional serum biomarkers and glycosylation pattern analysis, integrating results from all measurements through a unified algorithm that weighs different biomarkers based on their predictive value for HCC
2Measurement precision
If multiple serum biomarkers and glycosylation patterns are measured, then the sensitivity and specificity for HCC detection improve significantly, but the complexity of the detection system increases
Solution Approach 1:
The system performs preliminary actions by removing IgG and IgM proteins from the serum sample before measuring the biomarkers. This pre-treatment step simplifies subsequent measurements by eliminating interfering substances, thereby reducing the overall complexity of the detection system while maintaining high measurement precision
Solution Approach 2:
The patent changes the measurement parameters by focusing on specific glycosylation patterns (such as fucosylation status) of serum proteins rather than measuring protein quantity alone. This parameter transformation enables more sensitive detection of HCC while the automated analysis algorithm manages the complexity of multi-parameter measurement
Data Source
AI summary
Provided are methods, assays, and kits for detecting hepatocellular carcinoma, as well as methods for stratifying subjects among higher and lower risk categories for having hepatocellular carcinoma, and methods of treating and managing treatment of subjects that are suspected or at risk of having hepatocellular carcinoma. Although previous work has attempted to address the need for a highly sensitive, early predictor of hepatocellular carcinoma by assessment of one or more biological factors, none have approached the degree of sensitivity that is required for clinically relevant determination of whether a subject, especially a non-symptomatic subject, has that condition. The present inventors have discovered that certain combinations of factors fulfill this need by conferring a high level of accuracy that was not previously attainable.